Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Irvine, California and other locations
Dates
study started
completion around

Description

Summary

Long-term follow-up of subjects who received ST-920 in a previous trial (ST-920-201) and completed at least 52 weeks post-infusion follow-up in their primary protocol. Enrolled subjects will be followed for a total of up to 5 years following ST-920 infusion.

Official Title

Long-Term Follow-up of Fabry Disease Subjects Who Were Treated With ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy

Details

Non-interventional, multi-center, long-term follow-up (LTFU) study of subjects dosed with ST-920 in the clinical study ST-920-201. All subjects dosed in the study who completed at least 52 weeks post-infusion follow-up in their primary protocol will be offered to participate. Subjects who enroll will be monitored for a total of up to 5 years following ST-920 infusion.

Keywords

Fabry Disease, Fabry Disease, Cardiac Variant, Gene Therapy, ST-920, Rare, Genetic, DNA, Sangamo, Long Term

Eligibility

You can join if…

Open to people ages 18 years and up

  • Subjects who received ST-920 therapy in a separate parent trial
  • Subjects who have consented to participate in this LTFU study.

You CAN'T join if...

-This study has no exclusion criteria

Locations

  • University of California, Irvine
    Irvine California 92697 United States
  • University of Iowa Hospital and Clinics
    Iowa City Iowa 52242 United States

Details

Status
accepting new patients by invitation only
Start Date
Completion Date
(estimated)
Sponsor
Sangamo Therapeutics
ID
NCT05039866
Study Type
Observational
Participants
Expecting 48 study participants
Last Updated